Alexion bags option on Stealth's phase 3 rare disease drug

Alexion bags option on Stealth's phase 3 rare disease drug

Source: 
Fierce Biotech
snippet: 

Alexion has put up $30 million to land an option to co-develop Stealth BioTherapeutics’ phase 3 primary mitochondrial myopathy (PMM) prospect. The agreement gives Alexion the chance to pick up most of the global rights to the mitochondria-targeted therapy after Stealth posts results from an ongoing late-phase study.